

# Duncan R Hewett

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5272171/publications.pdf>

Version: 2024-02-01

17  
papers

528  
citations

858243

12  
h-index

993246

17  
g-index

17  
all docs

17  
docs citations

17  
times ranked

1185  
citing authors

#	ARTICLE	IF	CITATIONS
1	Expression of the chemokine receptor CCR1 promotes the dissemination of multiple myeloma plasma cells &lt;i>in vivo&lt;/i>. <i>Haematologica</i> , 2021, 106, 3176-3187.	1.7	11
2	Targeted Disruption of Bone Marrow Stromal Cell-Derived Gremlin1 Limits Multiple Myeloma Disease Progression <i>In Vivo</i> . <i>Cancers</i> , 2020, 12, 2149.	1.7	6
3	Characterization of the role of Samsn1 loss in multiple myeloma development. <i>FASEB BioAdvances</i> , 2020, 2, 554-572.	1.3	3
4	GLIPR1 expression is reduced in multiple myeloma but is not a tumour suppressor in mice. <i>PLoS ONE</i> , 2020, 15, e0228408.	1.1	2
5	Twist-1 is upregulated by NSD2 and contributes to tumour dissemination and an epithelial-mesenchymal transition-like gene expression signature in t(4;14)-positive multiple myeloma. <i>Cancer Letters</i> , 2020, 475, 99-108.	3.2	22
6	Subclonal evolution in disease progression from MGUS/SMM to multiple myeloma is characterised by clonal stability. <i>Leukemia</i> , 2019, 33, 457-468.	3.3	96
7	Clodronate-Liposome Mediated Macrophage Depletion Abrogates Multiple Myeloma Tumor Establishment <i>In Vivo</i> . <i>Neoplasia</i> , 2019, 21, 777-787.	2.3	53
8	A niche-dependent myeloid transcriptome signature defines dormant myeloma cells. <i>Blood</i> , 2019, 134, 30-43.	0.6	99
9	Using genomics to better define high-risk MGUS/SMM patients. <i>Oncotarget</i> , 2018, 9, 36549-36550.	0.8	2
10	Cutting edge genomics reveal new insights into tumour development, disease progression and therapeutic impacts in multiple myeloma. <i>British Journal of Haematology</i> , 2017, 178, 196-208.	1.2	17
11	HIF-2 $\alpha$ Promotes Dissemination of Plasma Cells in Multiple Myeloma by Regulating CXCL12/CXCR4 and CCR1. <i>Cancer Research</i> , 2017, 77, 5452-5463.	0.4	41
12	DNA Barcoding Reveals Habitual Clonal Dominance of Myeloma Plasma Cells in the Bone Marrow Microenvironment. <i>Neoplasia</i> , 2017, 19, 972-981.	2.3	18
13	Sphingosine kinase 2 inhibition synergises with bortezomib to target myeloma by enhancing endoplasmic reticulum stress. <i>Oncotarget</i> , 2017, 8, 43602-43616.	0.8	37
14	PTTG1 expression is associated with hyperproliferative disease and poor prognosis in multiple myeloma. <i>Journal of Hematology and Oncology</i> , 2015, 8, 106.	6.9	29
15	Therapeutic targeting of N $\alpha$ -cadherin is an effective treatment for multiple myeloma. <i>British Journal of Haematology</i> , 2015, 171, 387-399.	1.2	25
16	Tetraspanin 7 (TSPAN7) expression is upregulated in multiple myeloma patients and inhibits myeloma tumour development <i>in vivo</i> . <i>Experimental Cell Research</i> , 2015, 332, 24-38.	1.2	31
17	SAMSN1 Is a Tumor Suppressor Gene in Multiple Myeloma. <i>Neoplasia</i> , 2014, 16, 572-585.	2.3	36